Back to today’s briefing

Story perspectives

Semaglutide Reduces MASH Symptoms in 72-Week Study

10/10/2025

46 3

Summary

Story summary

Metabolic dysfunction-associated steatohepatitis (MASH) patients on semaglutide showed significant reductions in noninvasive tests (NITs) after 72 weeks.
Improvements appeared by 28 weeks, with more responders in the semaglutide group than in placebo.
The trial enrolled 202 patients on semaglutide and 66 on placebo, assessing 17 NITs; results may be limited by a small, predominantly White cohort and Novo Nordisk funding.

1 of 1

Story summary

Metabolic dysfunction-associated steatohepatitis (MASH) patients on semaglutide showed significant reductions in noninvasive tests (NITs) after 72 weeks.
Improvements appeared by 28 weeks, with more responders in the semaglutide group than in placebo.
The trial enrolled 202 patients on semaglutide and 66 on placebo, assessing 17 NITs; results may be limited by a small, predominantly White cohort and Novo Nordisk funding.